Sign in
Taking peoplePhase 1

VC005 tablets for teenagers with severe alopecia areata

Tests VC005 tablets in adolescents with severe alopecia areata.

Key facts

Who runs it
Jiangsu vcare pharmaceutical technology co., LTD
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
Status
Recruiting
Phase
Phase 1
People taking part
24 people, planned
Started
22 Sept 2026
Expected to end
30 Dec 2027
Type of study
Interventional, 2 groups
Treatments tested
  • VC005 tablets
Record updated
20 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for teenagers with severe alopecia areata, a condition where hair falls out in patches. It tests VC005 tablets.

Age
12 to 18 years (12 included, 18 not included).
Sex
All sexes can join.
Disease stage
Severe alopecia areata. The diagnosis must be confirmed at screening and at the start visit.

Main reasons for not taking part

  • Body weight under 40 kg (88 lb).
  • Being pregnant or breastfeeding, or planning to be during the study.
  • Acute diffuse alopecia areata, a fast, spread-out form of hair loss.
  • Other types of hair loss that could affect the assessment, such as traction alopecia or hair loss from thyroid disease.
  • Other scalp diseases, such as scalp psoriasis, dermatitis or tinea capitis (fungal scalp infection).

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • The subject fully understands this study and is able to comply with the relevant trial procedures. The subject and their legal guardian voluntarily sign the informed consent form (ICF)
  • Age 12 to 18 years inclusive (including 12 years old, excluding 18 years old) at the time of signing the ICF, both genders, with body weight ≥ 40 kg
  • Subjects must meet the diagnostic criteria for alopecia areata (AA) at both screening and baseline visits

Who cannot take part

  • Subjects with a current diagnosis of other types of alopecia that may interfere with the evaluation of AA, including but not limited to traction alopecia, cicatricial alopecia, telogen effluvium, androgenetic alopecia, syphilitic alopecia, anagen effluvium, folliculotropic mycosis fungoides, or alopecia caused by thyroid disease, etc
  • Subjects with other scalp diseases that may affect the assessment of AA, such as scalp psoriasis, dermatitis, tinea capitis, etc
  • Women who are pregnant or breastfeeding, or subjects who plan to become pregnant or breastfeed during the study period
  • Subjects with a current diagnosis of acute diffuse alopecia areata (AA)

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 18 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a multicenter, open-label, non-randomized, dose-finding Phase I study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with severe alopecia areata (AA).

The 2 groups in the trial

  • VC005 Tablets Low Dose groupsTreatment being tested

    Treatment: VC005 tablets

  • VC005 Tablets High Dose groupsTreatment being tested

    Treatment: VC005 tablets

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I Study to Evaluate the Pharmacokinetics, Safety, and Preliminary Efficacy of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
Plain-language title
VC005 tablets for teenagers with severe alopecia areataGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT07762443, who can take part
Record updated
20 October 2026